More recently, the American Diabetes Association (ADA), in their 2022 guidelines, added GLP-1 RA to the standard medical care of diabetes and recommended their use in T2DM with ASCVD or with a high risk of ASCVD [75]. The gene discussed is GLP1R; the disease is diabetes mellitus.